Related Experiment Videos
Our further experience with bromhexine in keratoconjunctivitis sicca
Annals of Ophthalmology
|October 1, 1988
Summary
Bromhexine effectively treats dry eye disease (keratoconjunctivitis sicca) over six years. The medication is particularly beneficial for patients experiencing partial lacrimal gland dysfunction.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Keratoconjunctivitis sicca, commonly known as dry eye disease, is a prevalent condition affecting ocular surface health.
- Lacrimal gland dysfunction is a key factor contributing to the pathophysiology of dry eye disease.
Purpose of the Study:
- To evaluate the long-term efficacy of bromhexine in managing keratoconjunctivitis sicca.
- To assess the drug's effectiveness in patients with varying degrees of lacrimal gland involvement.
Main Methods:
- A six-year clinical experience study was conducted.
- Patients diagnosed with keratoconjunctivitis sicca were treated with bromhexine.
- Treatment outcomes were monitored over an extended period.
Main Results:
- Bromhexine demonstrated significant efficacy in the long-term treatment of keratoconjunctivitis sicca.
- The drug proved particularly effective in patients with partially involved lacrimal glands.
Conclusions:
- Bromhexine is a viable and effective therapeutic option for chronic dry eye management.
- Long-term administration of bromhexine supports sustained improvement in patients with partial lacrimal gland insufficiency.